Zai Lab (NASDAQ:ZLAB) Shares Gap Up – What’s Next?

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $32.93, but opened at $33.97. Zai Lab shares last traded at $34.46, with a volume of 82,968 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on ZLAB shares. Citigroup reiterated a “buy” rating and set a $69.00 price target (up previously from $66.00) on shares of Zai Lab in a report on Monday, August 11th. Wall Street Zen cut shares of Zai Lab from a “buy” rating to a “hold” rating in a report on Friday, June 27th. Jefferies Financial Group assumed coverage on shares of Zai Lab in a report on Monday, August 25th. They issued a “buy” rating and a $52.00 target price on the stock. Finally, Leerink Partners set a $75.00 target price on shares of Zai Lab and gave the stock an “outperform” rating in a report on Monday, June 30th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Zai Lab presently has an average rating of “Moderate Buy” and an average target price of $56.35.

Zai Lab Stock Performance

The stock has a market capitalization of $3.82 billion, a P/E ratio of -16.76 and a beta of 1.04. The company’s 50-day moving average price is $34.27 and its 200 day moving average price is $33.78.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.37) EPS for the quarter, hitting analysts’ consensus estimates of ($0.37). Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. The business had revenue of $109.98 million during the quarter, compared to analysts’ expectations of $125.66 million. Zai Lab has set its FY 2025 guidance at EPS. Analysts predict that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Insider Activity

In related news, CEO Ying Du sold 50,000 shares of Zai Lab stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $34.74, for a total transaction of $1,737,000.00. Following the completion of the transaction, the chief executive officer directly owned 536,962 shares of the company’s stock, valued at approximately $18,654,059.88. The trade was a 8.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Rafael Amado sold 3,000 shares of Zai Lab stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $35.00, for a total transaction of $105,000.00. Following the transaction, the insider directly owned 42,178 shares of the company’s stock, valued at approximately $1,476,230. This represents a 6.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 168,634 shares of company stock valued at $5,899,402 in the last quarter. 4.96% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zai Lab

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Kingsview Wealth Management LLC lifted its stake in shares of Zai Lab by 6.0% in the 1st quarter. Kingsview Wealth Management LLC now owns 9,323 shares of the company’s stock valued at $337,000 after purchasing an additional 529 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Zai Lab by 2.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company’s stock valued at $1,496,000 after purchasing an additional 1,200 shares during the period. Walleye Capital LLC lifted its stake in shares of Zai Lab by 6.4% in the 1st quarter. Walleye Capital LLC now owns 22,276 shares of the company’s stock valued at $805,000 after purchasing an additional 1,338 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Zai Lab by 13.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 12,544 shares of the company’s stock valued at $453,000 after purchasing an additional 1,483 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Zai Lab during the first quarter worth $75,000. Institutional investors own 41.65% of the company’s stock.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.